Stanford Alliance for Innovative Medicines (AIM) - Summer 2018 Call for Letters of Intent

The ideal project for Stanford AIM will have a compelling therapeutic rationale, an identified protein target that is amenable to therapeutic intervention, and sufficient evidence to support the rationale for a drug discovery effort. It is essential that the LOI identifies a novel target or a novel approach to a known target with a distinct advantage over existing approaches to that target. Stanford AIM is open to all therapeutic areas and modalities with an emphasis on small molecule or protein therapeutics at this time. The goal of Stanford AIM is to advance selected faculty projects through proof-of-concept in animals by leveraging in-kind access to discovery and preclinical development capabilities through Takeda.